Since launching in 2024, the Blüm range has supported Australian patients and dispensing pharmacies with precise oral cannabinoid formulations designed for long-term therapy and scheduled dosing.
Because these products are commonly supplied as ongoing maintenance therapy, cost and access play an important role in continuity of care and repeat dispensing. Based on patient feedback and observed cost barriers in longer-term oral cannabinoid therapy, pricing across the Blüm range has been updated to improve accessibility and support treatment continuity for appropriate patients.
These changes take effect from 1 March 2026.
Why pricing changes matter in long-term therapy
Oral cannabinoid therapy is often prescribed as a structured, ongoing treatment — not a short-term intervention. This means patients may rely on consistent access over months or years.
When cost becomes a barrier, patients may delay refills, reduce dosing, or discontinue therapy altogether. Over time, this can impact treatment stability and clinical outcomes.
Adjusting pricing to better reflect long-term use helps support:
- Treatment adherence
- Consistent dispensing
- Continuity of care
- Sustainable access for appropriate patients
Updated pricing overview
The pricing update applies to the Blüm pastille range supplied in 24-pack formats:
- Blüm Rest and Blüm Ease
Previously $119 RRP ($105 WSP) → New price $95 RRP ($81 WSP) - Blüm Still and Blüm Lift
Previously $99 ($84 WSP) → New price $85 ($71)
These adjustments aim to improve affordability while maintaining the same formulations, packaging, and product standards.
Why Blüm remains a gold standard baseline oral therapy option
Precise cannabinoid ratios for targeted therapy
Blüm pastilles are built around structured cannabinoid ratios that combine major and minor cannabinoids to support more targeted product selection and counselling.
Consistent per-pastille dosing
Blüm uses a homogenised formulation process to ensure consistent cannabinoid content per pastille. Fixed per-unit dosing supports prescribing clarity and safer titration.
Enhanced oral absorption design
Blüm pastilles use an emulsion system with plant-derived emulsifiers (including Quillaja saponaria extract) and high-oleic sunflower oil to improve cannabinoid solubility and oral absorption. This formulation approach is designed to support more efficient bioavailability compared with non-emulsified edible formats.
Child-safe packaging and dispensing clarity
Blüm packaging is standardised to support safe storage, dispensing accuracy, and clearer product identification across repeats. Child-resistant tins and clear label expression help reduce selection and handling errors.
• Child-resistant, tamper-evident tins
• Clear ratio and strength labelling
• QR-linked opening and CMI guidance
